VERZENIO
PeakNDAORALTABLETPriority Review
Approved
Sep 2017
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
2
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 9h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VERZENIO (abemaciclib) is an oral small-molecule cyclin-dependent kinase 4/6 (CDK4/6) inhibitor approved by the FDA in September 2017. It is used to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer in combination with endocrine therapy. The drug works by inhibiting CDK4/6 proteins that drive cell cycle progression in cancer cells.
$757MPart D
Peak4.9 years to LOEVERZENIO is at peak sales with strong Part D utilization, indicating a mature, well-established franchise requiring sustained commercial and medical support teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
A Prospective Post-Marketing Observational Safety Study of Verzenios® (Abemaciclib) Among Breast Cancer Patients in China Verzenios® (Abemaciclib) Among Breast
Started Mar 2022
1,500 enrolled
The Incidence of AEs and SAEs Receiving Verzenios® Over a Period of Approximately 24 Weeks
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread
Started Jun 2014
132 enrolled
Metastatic Breast Cancer
Why This Matters for Your Career
Worked on VERZENIO at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.